Albireo Pharma (ALBO) Reports Q1 Loss of $0.15, Miss on Revenues

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/29/2026

1. NOW
2. MSFT
3. GOOGL
4. FTNT
5. EBAY
6. CMG
7. TENB
8. KLAC
9. BIIB
10. ETSY

Go back to Albireo Pharma (ALBO) Reports Q1 Loss of $0.15, Miss on Revenues

Albireo Provides First Quarter 2018 Business Update

May 17, 2018 7:30 AM EDT

 First patient enrolled in Phase 3 trial of IBAT inhibitor A4250 in PFIC 

 Elobixibat in Japan becomes first IBAT inhibitor approved in the world 

 Management to host conference call and webcast today at 8:30 a.m. EDT 

BOSTON, May 17, 2018 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq: ALBO), a clinical-stage orphan pediatric liver disease company developing novel bile acid modulators, today provided corporate highlights for the beginning of 2018.

The beginning of 2018 has been a landmark period for Albireo, said Ron Cooper, President and... More